Eli Lilly: risk of diabetes reduced by 94% with tirzepatide
(CercleFinance.com) - On Tuesday Eli Lilly announced that its flagship drug tirzepatide reduces the risk of developing type 2 diabetes by 94% in adult patients with pre-diabetes, obesity or overweight.
Better known under the trade names Zepbound and Mounjaro, this molecule, administered as a 15 mg injection once a week, produced an average weight loss of 22.9%, compared with 2.1% in the placebo group over the 3-year period of the Phase III study.
In all, tirzepatide was evaluated in 1,032 pre-diabetic, obese or overweight adults over a period of 176 weeks, followed by an observation period of 17 weeks, for a total of 193 weeks.
The first results of the study, over a period of six months, were published in 2022 in the scientific journal New England Journal of Medicine.
Tirzepatide is a GIP and GLP-1 receptor agonist which activates the receptors of these two natural incretin hormones present in the body.
Eli Lilly says that obesity currently affects over 900 million people worldwide.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Better known under the trade names Zepbound and Mounjaro, this molecule, administered as a 15 mg injection once a week, produced an average weight loss of 22.9%, compared with 2.1% in the placebo group over the 3-year period of the Phase III study.
In all, tirzepatide was evaluated in 1,032 pre-diabetic, obese or overweight adults over a period of 176 weeks, followed by an observation period of 17 weeks, for a total of 193 weeks.
The first results of the study, over a period of six months, were published in 2022 in the scientific journal New England Journal of Medicine.
Tirzepatide is a GIP and GLP-1 receptor agonist which activates the receptors of these two natural incretin hormones present in the body.
Eli Lilly says that obesity currently affects over 900 million people worldwide.
Copyright (c) 2024 CercleFinance.com. All rights reserved.